Last Updated: November 16, 2026

Investigational Drug Information for INCB050465

« Back to Dashboard


What is the drug development status for INCB050465?

INCB050465 is an investigational drug.

There have been 32 clinical trials for INCB050465. The most recent clinical trial was a Phase 2 trial, which was initiated on May 24th 2021.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and Mayo Clinic.

There are one hundred and one US patents protecting this investigational drug and two hundred and ninety-five international patents.

Recent Clinical Trials for INCB050465
TitleSponsorPhase
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)Incyte CorporationPhase 3
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaIncyte CorporationPhase 3
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.Chinese PLA General HospitalPhase 2

See all INCB050465 clinical trials

Clinical Trial Summary for INCB050465

Top disease conditions for INCB050465
Top clinical trial sponsors for INCB050465

See all INCB050465 clinical trials

US Patents for INCB050465

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB050465 ⤷  Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB050465 ⤷  Start Trial Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB050465 ⤷  Start Trial Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
INCB050465 ⤷  Start Trial Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB050465

Drugname Country Document Number Estimated Expiration Related US Patent
INCB050465 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Start Trial
INCB050465 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Start Trial
INCB050465 Australia AU2015244044 2034-04-08 ⤷  Start Trial
INCB050465 Australia AU2020213313 2034-04-08 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

INCB050465 Development Update and Market Projection

Last updated: September 9, 2026

INCB050465, also known as parsaclisib, is an oral, selective phosphatidylinositol 3-kinase delta, or PI3Kδ, inhibitor developed by Incyte for B-cell malignancies. Incyte discontinued the clinical development program after the PI3K inhibitor class faced worsening regulatory, safety and commercial conditions. Parsaclisib has no FDA approval, no marketed product, no Orange Book listing and no established revenue base. Its near-term commercial value is therefore effectively zero unless Incyte or a partner restarts development.

What is INCB050465 and what was it intended to treat?

Parsaclisib was designed to inhibit PI3Kδ, an enzyme involved in B-cell receptor signaling and malignant B-cell survival. The candidate was evaluated primarily in hematologic cancers, including:

  • Relapsed or refractory follicular lymphoma
  • Marginal zone lymphoma
  • Diffuse large B-cell lymphoma
  • Chronic lymphocytic leukemia
  • Other B-cell non-Hodgkin lymphomas

The program was organized under the CITADEL clinical development program. Incyte pursued parsaclisib as a potentially more selective alternative to earlier PI3K inhibitors, including idelalisib and duvelisib.

PI3Kδ inhibition produced clinical activity in relapsed B-cell malignancies, but the class experienced serious safety issues involving infections, colitis, pneumonitis, hepatotoxicity and treatment-related mortality. These risks reduced the regulatory and commercial value of the entire therapeutic category.

What is the current development status of parsaclisib?

Incyte discontinued development of parsaclisib. The candidate is not an active late-stage commercial program and has not received FDA approval.

Development attribute Status
Generic name Parsaclisib
Development code INCB050465
Developer Incyte Corporation
Mechanism Selective PI3Kδ inhibitor
Route Oral
Primary disease focus Relapsed or refractory B-cell malignancies
Regulatory status Not approved
FDA application No approved NDA identified
Orange Book status No listing
Development status Discontinued
Commercial status Not marketed
Current revenue None attributable to parsaclisib

Incyte’s decision followed the broader deterioration of the PI3K inhibitor market. The company’s program had generated response data in lymphoma, but clinical activity did not overcome the class-level concerns around durability, immune-mediated toxicity and the need for complex safety monitoring.

What clinical results did INCB050465 produce?

Parsaclisib generated response signals in several lymphoma studies, particularly in follicular lymphoma and marginal zone lymphoma. The most important development activity occurred in the CITADEL program, which included phase 2 and phase 3 studies.

Reported results showed that parsaclisib could produce tumor responses in heavily pretreated patients. Earlier-stage studies indicated meaningful overall response rates in relapsed follicular lymphoma and marginal zone lymphoma. The commercial question was whether those responses could translate into a favorable benefit-risk profile against established therapies and newer targeted medicines.

The program faced several limitations:

  1. Responses were measured in diseases with multiple approved and emerging therapies.
  2. PI3Kδ inhibitors required safety-management protocols that limited treatment duration.
  3. The class had difficulty demonstrating a durable survival or quality-of-life advantage.
  4. Regulators became less receptive to broad development strategies for PI3K inhibitors.
  5. Competing therapies increasingly included BTK inhibitors, EZH2 inhibitors, CAR-T therapy, bispecific antibodies and antibody-drug conjugates.

The clinical data were therefore insufficient to support a sustainable commercial launch.

When did parsaclisib lose exclusivity and commercial momentum?

Parsaclisib did not reach the market, so it did not have a conventional branded-product exclusivity period. Its commercial loss occurred through development discontinuation rather than generic erosion.

A simplified timeline is:

Period Event
Mid-to-late 2010s Incyte advances parsaclisib into clinical testing for B-cell malignancies
2018-2020 CITADEL studies report clinical activity in lymphoma
2020-2021 PI3K inhibitor regulatory scrutiny increases following safety concerns involving marketed products
2021-2022 Incyte evaluates the strategic and regulatory viability of parsaclisib
2022 Parsaclisib development is discontinued
2023-2024 No FDA approval, commercial launch or active late-stage program emerges

The candidate therefore has no practical launch exclusivity, prescription share or revenue protection to defend.

What is the FDA regulatory status of INCB050465?

Parsaclisib is not FDA-approved. No FDA-approved indication, label, dosing regimen or post-marketing safety program exists for the compound.

The FDA’s experience with PI3K inhibitors materially affected the development environment. Idelalisib, duvelisib and umbralisib encountered significant safety and regulatory challenges. Umbralisib was withdrawn from the U.S. market after confirmatory evidence failed to sustain its benefit-risk profile. These events increased the evidentiary burden for subsequent PI3K inhibitor programs.

For parsaclisib, the regulatory barriers included:

  • Need for long-term safety follow-up
  • Concern over opportunistic infections
  • Immune-mediated adverse events
  • Potential treatment-related mortality
  • Difficulty establishing superior benefit over alternative therapies
  • Need for carefully selected patient populations and prophylaxis

No approved label means no FDA-recognized indication for substitution, no reference-listed drug status and no abbreviated new drug application pathway based on parsaclisib.

What is the Orange Book status of parsaclisib?

Parsaclisib has no Orange Book listing because Incyte did not obtain FDA approval for an NDA covering the product.

The absence of an Orange Book record has several consequences:

  • No listed U.S. patents tied to an approved product
  • No statutory patent certification pathway against an approved reference product
  • No conventional Paragraph IV challenge to an approved parsaclisib product
  • No Hatch-Waxman litigation record based on an approved parsaclisib NDA
  • No regulatory exclusivity attached to a marketed parsaclisib indication

Any future development would likely require a new regulatory strategy rather than a standard generic-entry defense.

Were there Paragraph IV challenges or patent litigation involving INCB050465?

No material Paragraph IV litigation or commercial patent dispute is associated with an approved parsaclisib product because the candidate never reached FDA approval.

Incyte may hold or have held patent rights covering the compound, salts, formulations, dosing regimens, combinations and therapeutic uses. Those rights would not create meaningful market protection without an approved and commercially viable product. The practical value of any remaining patents is limited by:

  • The discontinued clinical program
  • Lack of an approved reference product
  • No established prescriber base
  • Class-wide safety concerns
  • Competition from newer lymphoma therapies
  • The need to generate new clinical data for any revival

The expiration dates and enforceability of individual INCB050465 patent families should not be treated as commercial assets without a confirmed reactivation plan.

What formulations and methods of use were protected?

The development program likely depended on multiple layers of intellectual property rather than a single composition-of-matter right. Relevant categories include:

Compound patents

These cover parsaclisib and potentially related chemical structures, stereoisomers, salts and crystalline forms.

Formulation patents

These may cover oral tablets, excipient systems, dissolution characteristics, stability and manufacturing processes.

Method-of-use patents

Potential claims could cover treatment of follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia or other B-cell malignancies.

Combination patents

Potential combination claims could involve anti-CD20 antibodies, chemotherapy, BTK inhibitors or other targeted agents.

Because there is no approved product, the commercial enforceability of these categories is substantially lower than for the patent estate supporting a marketed oncology drug.

How does parsaclisib compare with competing PI3K inhibitors?

Drug Target Status Commercial outcome
Parsaclisib PI3Kδ Development discontinued No revenue
Idelalisib PI3Kδ Approved in selected hematologic cancers Commercially constrained by safety
Duvelisib PI3Kδ/PI3Kγ Approved for selected blood cancers Limited uptake and safety pressure
Umbralisib PI3Kδ/CK1ε Approval withdrawn Market removed
Copanlisib PI3Kα/PI3Kδ Approved for follicular lymphoma Narrower commercial role
Inavolisib PI3Kα Approved in a different oncology setting Demonstrates renewed interest in better-defined PI3K development

Parsaclisib’s selectivity was not enough to differentiate the program commercially. The market shifted toward drugs with clearer biomarker strategies, more manageable safety profiles or stronger outcomes in defined treatment lines.

What is the market projection for INCB050465?

The base-case market projection is zero commercial sales through the medium term because parsaclisib is discontinued and has no approved indication.

Scenario Probability direction Commercial outlook
Base case: program remains discontinued Highest No revenue
Limited revival in a narrow lymphoma population Low Small, specialized opportunity
Licensing to another oncology company Low Milestone value possible, but launch probability remains limited
Full relaunch across B-cell malignancies Very low Requires new clinical, regulatory and safety investment
Generic competition Not relevant currently No approved product to copy

A hypothetical relaunch would face a smaller market than the original development plan assumed. Follicular lymphoma and marginal zone lymphoma remain commercially meaningful indications, but the treatment landscape has changed. Physicians now have access to anti-CD20 regimens, immunomodulatory agents, EZH2 inhibitors, BTK pathway drugs, CAR-T therapies and bispecific antibodies.

A revived parsaclisib program would probably require:

  • A narrowly defined patient population
  • A differentiated safety protocol
  • Prospective infection prophylaxis
  • Stronger durability data
  • A clear combination strategy
  • Evidence against current standards of care
  • A regulatory agreement on confirmatory requirements

These requirements would increase development costs while reducing the addressable market.

Which companies are challenging the same market?

Parsaclisib would have competed with companies developing or marketing treatments for relapsed B-cell malignancies, including:

  • Gilead Sciences and Kite
  • AbbVie and Johnson & Johnson
  • Roche and Genentech
  • Novartis
  • Bristol Myers Squibb
  • BeiGene
  • AstraZeneca
  • MorphoSys and its commercial partners
  • Ipsen and other developers of targeted lymphoma therapies

The competitive threat is strongest from products that offer durable responses, outpatient administration or a more defined safety profile. CAR-T products and bispecific antibodies have expanded the treatment options available after multiple prior lines, while targeted oral drugs retain value where tolerability and convenience are favorable.

How strong is the remaining patent and licensing position?

The patent position is commercially weak in the absence of an active program. Incyte remains the principal development rights holder publicly associated with parsaclisib, and no major licensing transaction has established a new commercial owner or active co-development partner.

Potential asset value could exist in:

  • Chemical matter
  • Selective PI3Kδ inhibition
  • Combination use
  • Data generated in lymphoma
  • Manufacturing know-how
  • Safety-management experience

Those assets are unlikely to command a valuation comparable to an active phase 3 oncology program. A buyer would need to discount for clinical restart costs, regulatory risk and competition from approved or late-stage alternatives.

What generic launch risks exist?

There is no immediate generic-launch risk because parsaclisib has no approved product. The relevant risk is development abandonment rather than generic substitution.

If Incyte revived the program and obtained approval, generic risk would depend on:

  • Remaining composition-of-matter patent term
  • Validity of formulation and method-of-use patents
  • Pediatric or other regulatory exclusivity
  • Number of approved indications
  • Commercial uptake
  • Whether the approved product had a clinically meaningful niche

Without an approved reference product, generic manufacturers have no current pathway to launch parsaclisib through the conventional ANDA route.

Key Takeaways

  • INCB050465 is parsaclisib, an oral selective PI3Kδ inhibitor developed by Incyte.
  • Development was discontinued after clinical, regulatory and commercial problems affecting the PI3K inhibitor class.
  • Parsaclisib is not FDA-approved and has no Orange Book listing.
  • No material Paragraph IV litigation or generic challenge exists.
  • The candidate has no current commercial revenue.
  • Any remaining patent rights have limited value without program revival.
  • The base-case market forecast is zero sales.
  • A relaunch would require new clinical evidence, a narrow target population and a materially improved safety proposition.

FAQs

Is INCB050465 the same drug as parsaclisib?

Yes. INCB050465 is the development code for parsaclisib, an oral selective PI3Kδ inhibitor.

Can patients currently receive parsaclisib commercially?

No. Parsaclisib is not an FDA-approved marketed medicine.

Does parsaclisib have an approved lymphoma indication?

No. The candidate was studied in several B-cell malignancies but did not receive an approved indication.

Is parsaclisib likely to be licensed to another company?

A licensing transaction is possible in principle, but the discontinued status, PI3K class safety history and competitive lymphoma market make a major transaction unlikely without new clinical evidence.

Could parsaclisib return to clinical development?

A return would require substantial additional investment and a new benefit-risk strategy. The most plausible route would be a narrowly selected lymphoma population or a combination regimen supported by new biomarker and safety data.

References

  1. Incyte Corporation. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  2. Incyte Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  3. U.S. Food and Drug Administration. (2022). FDA approves umbralisib for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
  4. U.S. Food and Drug Administration. (2022). FDA alerts patients and health care professionals about safety concerns with PI3K inhibitors.
  5. ClinicalTrials.gov. (n.d.). Studies of parsaclisib in patients with relapsed or refractory B-cell malignancies. U.S. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.